Cargando…

A Practical Guide to Relugolix: Early Experience With Oral Androgen Deprivation Therapy

BACKGROUND: Relugolix is the newest form of androgen deprivation therapy (ADT) approved for prostate cancer. However, as an oral drug, several real-world concerns exist, particularly medication compliance, safety with other androgen receptor-targeted agents, and financial burden to patients. METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kasparian, Saro, Wei, Oren, Tsai, Ni-Chun, Palmer, Joycelynne, Pal, Sumanta, Lyou, Yung, Dorff, Tanya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Genitourinary Cancer
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10400130/ https://www.ncbi.nlm.nih.gov/pubmed/36888587 http://dx.doi.org/10.1093/oncolo/oyad036

Ejemplares similares

Hormonal manipulation in androgen signaling: a narrative review on using novel androgen therapy agents to optimize clinical outcomes and minimize side effects for prostate cancer patients
por: Lyou, Yung, et al.
Publicado: (2021)

Relugolix – The novel oral androgen deprivation therapy for prostate cancer
por: Jena, Rahul
Publicado: (2020)

Twelve-Month Follow-up of the Immune Response After COVID-19 Vaccination in Patients with Genitourinary Cancers: A Prospective Cohort Analysis
por: Meza, Luis, et al.
Publicado: (2023)

Bipolar Androgen Therapy Followed by Androgen Receptor Inhibition as Sequential Therapy for Prostate Cancer
por: Denmeade, Samuel R, et al.
Publicado: (2023)

Activity of Tivozanib in Non-clear Cell Renal Cell Carcinoma: Subgroup Analysis From a Phase II Randomized Discontinuation Trial
por: Barata, Pedro C, et al.
Publicado: (2023)

Targeting the N-Terminal Domain of the Androgen Receptor: A New Approach for the Treatment of Advanced Prostate Cancer
por: Antonarakis, Emmanuel S., et al.
Publicado: (2016)

Talazoparib, a Poly(ADP-ribose) Polymerase Inhibitor, for Metastatic Castration-resistant Prostate Cancer and DNA Damage Response Alterations: TALAPRO-1 Safety Analyses
por: Mehra, Niven, et al.
Publicado: (2022)

Health-Related Quality of Life Outcomes With Two Different Starting Doses of Lenvatinib in Combination With Everolimus for Previously Treated Renal Cell Carcinoma
por: Bergerot, Cristiane, et al.
Publicado: (2023)

A Phase I/II Trial of Fairly Brief Androgen Suppression and Stereotactic Radiation Therapy for High-Risk Prostate Cancer (FASTR-2): Preliminary Results and Toxicity Analysis
por: Callan, Laura, et al.
Publicado: (2019)

Salvage image guided radiation therapy to the prostate after cryotherapy failure
por: Hopper, Austin B., et al.
Publicado: (2017)

Patients’ Perceptions Regarding the Relevance of Items Contained in the Functional Assessment of Cancer Therapy Kidney Symptom Index-19
por: Bergerot, Cristiane Decat, et al.
Publicado: (2023)

Wnt/β-Catenin Signaling and Immunotherapy Resistance: Lessons for the Treatment of Urothelial Carcinoma
por: Chehrazi-Raffle, Alexander, et al.
Publicado: (2021)

Adherence to Oral Treatments in Older Patients with Advanced Prostate Cancer, the ADHERE Study: A Prospective Trial of the Meet-URO Network
por: Rescigno, Pasquale, et al.
Publicado: (2022)

Relugolix: a novel androgen deprivation therapy for management of patients with advanced prostate cancer
por: Saad, Fred, et al.
Publicado: (2021)

Radiomics-guided therapy for bladder cancer: Using an optimal biomarker approach to determine extent of bladder cancer invasion from t2-weighted magnetic resonance images
por: Tong, Yubing, et al.
Publicado: (2018)

Percutaneous Image-Guided Nodal Biopsy After 11C-Choline PET/CT for Biochemically Recurrent Prostate Cancer: Imaging Predictors of Disease and Clinical Implications
por: Welch, Brian T., et al.
Publicado: (2018)

Ten-Year Results From a Phase II Study on Image Guided, Intensity Modulated Radiation Therapy With Simultaneous Integrated Boost in High-Risk Prostate Cancer
por: Ekanger, Christian, et al.
Publicado: (2019)

(11)C-Choline PET Guided Salvage Radiation Therapy for Isolated Pelvic and Paraortic Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Rationale and Early Genitourinary or Gastrointestinal Toxicities
por: Jethwa, Krishan R., et al.
Publicado: (2019)

Plasma Exosomal AKR1C3 mRNA Expression Is a Predictive and Prognostic Biomarker in Patients with Metastatic Castration-Resistant Prostate Cancer
por: Zhu, Sha, et al.
Publicado: (2022)

Difficulties in Defining Oligometastatic Prostate Cancer: Implications for Clinical Trial Accrual and Community Practice Adoption of Metastasis-Directed Therapy Approaches
por: Dorff, Tanya Barauskas, et al.
Publicado: (2023)

Four Cycles of Etoposide plus Cisplatin for Patients with Good‐Risk Advanced Germ Cell Tumors
por: Funt, Samuel A., et al.
Publicado: (2021)

Stereotactic body radiation therapy for medically inoperable, clinically localized, urothelial carcinoma of the renal pelvis: A case report
por: Evans, Jaden D., et al.
Publicado: (2017)

Late toxicity after post-prostatectomy intensity modulated radiation therapy: Evaluating normal-tissue sparing guidelines
por: Akthar, Adil S., et al.
Publicado: (2018)

Initial toxicity, quality-of-life outcomes, and dosimetric impact in a randomized phase 3 trial of hypofractionated versus standard fractionated proton therapy for low-risk prostate cancer
por: Vargas, Carlos E., et al.
Publicado: (2018)

Prostate Stereotactic Body Radiation Therapy With a Focal Simultaneous Integrated Boost: Acute Toxicity and Dosimetry Results From a Prospective Trial
por: McDonald, Andrew M., et al.
Publicado: (2018)

Transitioning From a Low-Dose-Rate to a High-Dose-Rate Prostate Brachytherapy Program: Comparing Initial Dosimetry and Improving Workflow Efficiency Through Targeted Interventions
por: Solanki, Abhishek A., et al.
Publicado: (2018)

The Perineural Invasion Paradox: Is Perineural Invasion an Independent Prognostic Indicator of Biochemical Recurrence Risk in Patients With pT2N0R0 Prostate Cancer? A Multi-Institutional Study
por: Kraus, Ryan Douglas, et al.
Publicado: (2018)

Analysis of Gastrointestinal Toxicity in Patients Receiving Proton Beam Therapy for Prostate Cancer: A Single-Institution Experience
por: Lee, Howard J., et al.
Publicado: (2018)

Radiation-related Lymphopenia after Pelvic Nodal Irradiation for Prostate Cancer
por: Schad, Michael D., et al.
Publicado: (2019)

Early Tolerance Outcomes of Stereotactic Hypofractionated Accelerated Radiation Therapy Concomitant with Pelvic Node Irradiation in High-risk Prostate Cancer
por: Pinitpatcharalert, Attapol, et al.
Publicado: (2019)

Regional Differences in the Treatment of Localized Prostate Cancer: An Analysis of Surgery and Radiation Utilization in the United States
por: Scherzer, Nickolas D., et al.
Publicado: (2019)

Dose-Escalated Intensity Modulated Radiation Therapy for Prostate Cancer: 15-Year Outcomes Data
por: Weg, Emily S., et al.
Publicado: (2019)

Pathologic Complete Response After Chemoradiation of a Massive Primary Urethral Carcinoma
por: Singh, Tanmay, et al.
Publicado: (2019)

Evaluating the potential benefit of reduced planning target volume margins for low and intermediate risk patients with prostate cancer using real-time electromagnetic tracking
por: Chaurasia, Avinash R., et al.
Publicado: (2018)

Stereotactic body radiation therapy for adrenal gland metastases: Outcomes and toxicity
por: Toesca, Diego A.S., et al.
Publicado: (2018)

The PROFILE Feasibility Study: Targeted Screening of Men With a Family History of Prostate Cancer
por: Castro, Elena, et al.
Publicado: (2016)

Fibroblast Growth Factor Receptor (FGFR) Inhibitors in Urothelial Cancer
por: Garje, Rohan, et al.
Publicado: (2020)

Building a High-Dose-Rate Prostate Brachytherapy Program With Real-Time Ultrasound-Based Planning: Initial Safety, Quality, and Outcome Results
por: Zhang, Hong, et al.
Publicado: (2020)

Gantry-Mounted Linear Accelerator–Based Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer
por: Dang, Audrey T., et al.
Publicado: (2019)

Long‐Term Experience of Chemoradiotherapy Combined with Deep Regional Hyperthermia for Organ Preservation in High‐Risk Bladder Cancer (Ta, Tis, T1, T2)
por: Merten, Ricarda, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_bfbr5cf7oj6jpdf611csjflee9